NASDAQ · NUWE

Nuwellis, Inc.

$1.94 -$0.11 (-5.61%) 1D Market open
Session Pulse Regular session 1 mentions on Fri No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →

Key Metrics

$189.01K
Market cap
P/E · TTM
$8.77M
Revenue · TTM
−$19.05M
Net income
EPS · TTM $-182.90
Dividend yield
Free cash flow −$11.51M
Beta · 1Y 1.17
EBITDA · TTM
Gross margin 65.5%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Feb 3 high, the share price fell 99%.

    Peak close $136.15 on Feb 3; trough close $1.99 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -99%
  • Jul 24
    A material event was filed (Form 8-K).

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 24
    The stock moved -30.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 24
  • Jun 5
    The stock moved -61.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$189.01K
Enterprise value
Shares outstanding92.2K
52-wk range$1.71 – $172.90
Avg volume · 20D72.8K
Net cash
Book value / share$25.55
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNASDAQ
About Nuwellis, Inc.
IPO dateFeb 16, 2012
Employees38

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.02
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 65.5%
Operating -217.2%
Net -217.2%
FCF -131.2%
ROE / ROIC -414.6% · -3,295.5%

Financial Health

Current ratio1.56
Quick ratio1.09
Debt / equity
Debt / EBITDA
Net cash
Working capital$2.10M

Cash Flow · TTM

Operating CF −$11.39M
Capex −$120.00K
Free cash flow −$11.51M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-71.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings